UBS Group
CUE icon

UBS Group’s Cue Biopharma CUE Stock Holding History

UBS Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3K Buy
2,945
+1,383
+89% +$12.9K ﹤0.01% 7918
2025
Q4 		$14.3K Sell
1,562
-5,077
-76% -$93.3K ﹤0.01% 8016
2025
Q3 		$143K Sell
6,639
-3,114
-32% -$73.1K ﹤0.01% 6879
2025
Q2 		$200K Buy
9,753
+7,709
+377% +$164K ﹤0.01% 6726
2025
Q1 		$55.9K Buy
2,044
+100
+5% +$3.71K ﹤0.01% 7503
2024
Q4 		$63.6K Sell
1,944
-529
-21% -$19.9K ﹤0.01% 7149
2024
Q3 		$56.1K Buy
2,473
+506
+26% +$11K ﹤0.01% 6739
2024
Q2 		$73.2K Sell
1,967
-1,132
-37% -$56K ﹤0.01% 6397
2024
Q1 		$176K Sell
3,099
-210
-6% -$14.8K ﹤0.01% 5943
2023
Q4 		$262K Buy
3,309
+671
+25% +$48K ﹤0.01% 5601
2023
Q3 		$182K Sell
2,638
-39
-1% -$3.81K ﹤0.01% 5423
2023
Q2 		$293K Buy
2,677
+743
+38% +$87.3K ﹤0.01% 5225
2023
Q1 		$207K Buy
1,934
+1,129
+140% +$108K ﹤0.01% 5364
2022
Q4 		$68.8K Hold
805
– – ﹤0.01% 6460
2022
Q3 		$54K Sell
805
-142
-15% -$12.2K ﹤0.01% 6278
2022
Q2 		$71K Buy
947
+91
+11% +$10.6K ﹤0.01% 5667
2022
Q1 		$126K Sell
856
-2,787
-77% -$591K ﹤0.01% 5720
2021
Q4 		$1.24M Buy
3,643
+1,690
+87% +$654K ﹤0.01% 4200
2021
Q3 		$854K Buy
1,953
+1,052
+117% +$367K ﹤0.01% 4323
2021
Q2 		$315K Sell
901
-846
-48% -$328K ﹤0.01% 5050
2021
Q1 		$640K Buy
1,747
+996
+133% +$410K ﹤0.01% 4676
2020
Q4 		$282K Buy
751
+31
+4% +$12.4K ﹤0.01% 5008
2020
Q3 		$325K Hold
720
– – ﹤0.01% 4486
2020
Q2 		$529K Sell
720
-312
-30% -$226K ﹤0.01% 4077
2020
Q1 		$439K Sell
1,032
-929
-47% -$450K ﹤0.01% 4084
2019
Q4 		$933K Buy
1,961
+344
+21% +$108K ﹤0.01% 4286
2019
Q3 		$409K Buy
1,617
+406
+34% +$97.5K ﹤0.01% 4728
2019
Q2 		$326K Buy
1,211
+199
+20% +$49.5K ﹤0.01% 4590
2019
Q1 		$235K Sell
1,012
-233
-19% -$44.3K ﹤0.01% 4517
2018
Q4 		$175K Buy
1,245
+375
+43% +$68.1K ﹤0.01% 5065
2018
Q3 		$236K Buy
870
+98
+13% +$28.3K ﹤0.01% 4931
2018
Q2 		$275K Buy
772
+649
+528% +$258K ﹤0.01% 4740
2018
Q1 		$52K Buy
+123
New +$56.1K ﹤0.01% 5682

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

UBS Group's CUE Position: Q1 2026 in Review

UBS Group increased its Cue Biopharma (CUE) stake by 89% in Q1 2026, buying an estimated $12.9K and bringing the position to 2,945 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7918.

UBS Group first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.24M in Q4 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • UBS Group held 2,945 shares of Cue Biopharma worth $20.3K as of Q1 2026.
  • UBS Group bought 1,383 Cue Biopharma shares in Q1 2026, an estimated $12.9K.
  • Cue Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7918 holding.
  • UBS Group first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • UBS Group's Cue Biopharma position peaked at $1.24M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.